Attorneys At Law.

Personal Injury

Personal Injury Lawyer

For a free, confidential legal consultation, submit your Personal Injury injury claim or call 1-800-471-3980 now.

If you are looking for a firm that can handle Personal Injury lawsuits, or are simply unsure if you have a case, there is no obligation to discuss your case with one of GPW's attorneys. Contact us today.

About Personal Injury


Personal Injury news feed.

Vioxx caused Texas man’s death; Merck & Co. required to pay $253 million

August 19th, 2005. Have a Vioxx legal claim? For a free, confidential legal consultation, Submit your Vioxx injury claim or call 1-800-471-3980 now. Of Note: Actual damages: $24.4 Million Punitive Damages: $229 Million $229 Million is the amount Merck made in sales of Vioxx from Oct. 2001, when FDA suggested the label change, to the ... [More >>]

Lilly and Plaintiffs’ Attorneys Enter Into an Agreement in Principle to Settle Majority of Zyprexa® Product Liability Litigation

June 9th, 2005. (Press Release) Eli Lilly and Company announced today that it has entered into an agreement in principle with plaintiffs' attorneys involved in Zyprexa liability litigation to settle a majority of the claims against Lilly relating to the medication. When finalized, the settlement will resolve the majority ... [More >>]

FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients

April 11th, 2005. (Press Release) The Food and Drug Administration (FDA) today issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” These drugs are approved for the treatment of schizophrenia and mania, but ... [More >>]

FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

April 7th, 2005. (Press Release) The Food and Drug Administration (FDA) today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective NSAID medications. A list of these products is available on the FDA web site. ... [More >>]

New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular Profile

April 7th, 2005. (Press Release) Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs ... [More >>]

Arthritis Drug Bextra Pulled; FDA Requests Revised Label on OTC NSAIDS

April 7th, 2005. What should I do if I am currently taking Bextra? You should speak with your doctor immediately to investigate options to discontinue Bextra and seek alternative treatments. Stevens-Johnson Syndrome In addition to cardiovascular problems, Bextra has been linked to a rare but sometimes ... [More >>]

New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular Profile

April 7th, 2005. (Press Release) Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all COX-2 pain relievers and all NSAIDs, including older non-specific drugs ... [More >>]

Forbes Regional Hospital alerts 200 patients who received colonoscopies that they may be at risk for hepatitis, HIV

March 31st, 2005. Did you receive a colonoscopy at Forbes Regional Hospital? Here is a checklist of important facts for patients who received the procedure at Forbes in Monroeville: Colonoscopes were inadequately cleaned between October 28, 2004 and February 26, 2005. There is a small risk of hepatitis and HIV as a result of the inadequate ... [More >>]

FDA Statement on the Halting of a Clinical Trial of the Cox-2 Inhibitor Celebrex

December 17th, 2004. (Press Release) The FDA today released the following statement on the halting of a clinical trial of the Cox-2 inhibitor Celebrex (celecoxib): The Food and Drug Administration (FDA) learned last night from the National Cancer Institute (NCI) and Pfizer, Inc., that NCI has stopped drug administration in an ongoing clinical trial ... [More >>]

Merck & Co., Inc. Response to an Editorial Posted on the New England Journal of Medicine Web Site

December 8th, 2004. In response to an editorial that appeared today on the New England Journal of Medicine website, Merck & Co., Inc. believes that it is important to emphasize that the company promptly and appropriately disclosed the results of the VIGOR (VIOXX Gastrointestinal Outcomes Research) study. Merck correctly communicated about the benefits ... [More >>]

Pittsburgh, PA. Greensburg, PA. Johnstown, PA. West Virginia. Saginaw, MI Allen Park, MI.